COMP <GO>
HRMY vs LLY // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Harmony Biosciences Holdings Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: HRMY 4
— LLY 8
■ METRIC PARITY
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
options-implied-move
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
options-implied-move
6.77%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | 83.64% | -6.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | 32.36% | +30.64 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | 36.4x | -28.62 | HRMY | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | 2.30% | +13.18 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | 40.21% | -16.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 31.90% | -13.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | 45.51% | -24.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 9.29 | -3.91 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 66.6 | -15.54 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 26.3x | -14.35 | HRMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.25B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | LLY REV | HRMY GROSS % | LLY GROSS % | HRMY FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $65.18B | 77.2% | 83.0% | $347.9M | $16.81B |
| FY 2024 | $714.7M | $45.04B | 78.1% | 81.3% | $218.7M | $8.82B |
| FY 2023 | $582.0M | $34.12B | — | 79.3% | $219.4M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
LLY // BETA 0.51